{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "CGEM",
  "name": "Cullinan Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/CGEM/",
  "json_url": "https://orbyd.app/dossiers/CGEM.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout until 2H-2026 — a between-catalysts base, not a catalyst buy. The 2026-08-07 Q2 print is a cash/runway checkpoint, not a data event.",
  "invalidation_trigger": "A weekly close below $15.77 round-trips the June-data bull flag and the rising structure off the $5.68 low; a CRS or durability miss in expanded CLN-978 cohorts, or the CD19-TCE-in-autoimmune theme flipping SATURATED with no replacement leg, would confirm the break.",
  "catalyst_date": "2026-08-07",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics",
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Next hard-dated binary is zipalertinib PDUFA 2027-02-27 (partnered, Taiho); CLN-978 2H-2026 updates are undated — watch ACR (~Nov) for a conference slot.",
    "Q2-2026 print ~est. 2026-08-11 — cash/runway update, not a data event; earnings-blackout awareness for that window.",
    "Cash $351.9M + $41.4M long-term (Q1-2026), runway guided into 2029 — no near-term financing pressure through the 2H data.",
    "Immunology Day (2026-06-10) was the last big catalyst;",
    "Next hard-dated binary is zipalertinib PDUFA 2027-02-27 (partnered, Taiho); CLN-978 2H-2026 updates are undated — watch ACR Convergence (~Nov 2026) for a conference slot.",
    "Q2-2026 print firmed to ~2026-08-07 (was est. 08-11) — cash/runway update, not a data event; honor the earnings-blackout window around it.",
    "Cash + investments $393.3M (2026-03-31), runway guided into 2029; burn ~$50M/quarter keeps eventual dilution live if the tape cools before 2H data.",
    "Analyst band recalibrated to median $30 / range $22–$38 / consensus ~$31.55 (16 analysts); H.C. Wainwright $33 from $28. The prior $46 Clear Street tag is now above the live range — dropped."
  ],
  "body_markdown": "## Current Thesis\nCGEM re-rated roughly 3x off its $5.68 52-week low as the story turned from a stalled oncology shop (the 2024 Cullinan Oncology → Cullinan Therapeutics rename) into a front-line name in the CD19 T-cell-engager-for-autoimmune wave. The engine is CLN-978, a subcutaneous CD19xCD3 bispecific: Phase 1 data at EULAR (2026-06-06) and the Immunology Day (2026-06-10) showed single-dose remissions in treatment-refractory lupus and rheumatoid arthritis, deep B-cell depletion in blood and tissue, and clean safety to 30 µg across 29 patients enrolled as of 2026-05-15. Underneath sits partnered commercial optionality — zipalertinib (Taiho), NDA accepted 2026-04-27, PDUFA 2027-02-27. The theme is ACCELERATING and CGEM is a leader inside it, but the biggest readout is already priced and the tape has slipped from ~$18 to ~$17.10 (2026-07-24). With no dated clinical readout until undated 2H-2026 updates, this is a between-catalysts consolidation under the $19.43 high, and the next scheduled event is a cash-and-runway print, not a data catalyst.\n\n## Bull Case\n- CLN-978 delivered single-dose clinical remissions in refractory SLE and RA with deep, dose-dependent B-cell depletion in peripheral blood and tissue, favorable safety to 30 µg (EULAR 2026-06-06; Immunology Day 2026-06-10, n=29) — validating an off-the-shelf subcutaneous alternative to autologous CD19 CAR-T in autoimmune disease.\n- First RA multi-dose-regimen cohort showed robust efficacy including remission in a poly-refractory patient (2026-06-10), extending the signal beyond the single-dose data; further SLE/RA/Sjögren's updates guided for 2H-2026.\n- Zipalertinib carries partnered near-approval optionality with no program dilution risk: FDA accepted the NDA 2026-04-27 for EGFR exon 20 insertion NSCLC on a REZILIENT1 Phase 2b that met its ORR primary, PDUFA 2027-02-27.\n- Balance sheet removes the financing gun: $393.3M cash and investments at 2026-03-31, runway guided into 2029 — funded through the 2H-2026 catalysts.\n- Pipeline breadth beyond the lead: velinotamig (BCMA T-cell engager) added first autoimmune multi-dose data 2026-06-10, and CLN-049 (FLT3xCD3) took FDA orphan drug designation in R/R AML on 2026-05-19 (fast track already granted Dec 2025).\n- Sell-side is chasing, not leading: 16-analyst median target $30 (range $22–$38, consensus ~$31.55) against a ~$17.10 spot, with H.C. Wainwright lifting its target to $33 from $28; 12 rate it Strong Buy.\n\n## Bear Case\n- Pre-revenue equity is wholly a data bet: Q1-2026 net loss $49.7M (R&D $42.1M, G&A $11.6M) on a $637.8M accumulated deficit, with cash down from $439.0M (2025-12-31) to $393.3M (2026-03-31) at ~$50M/quarter burn — dilution stays live if the tape cools before the next readout.\n- The n=29 single-dose CLN-978 dataset is early and thin; competing CD19/CAR-T-in-autoimmune programs (Cabaletta, Kyverna, large-cap bispecifics) can leapfrog on durability or safety, and any CRS or neurotoxicity signal in expanded cohorts breaks the clean-safety leg.\n- The narrative's biggest fuel — Immunology Day — is spent, and with no dated near-term data the tape has already begun drifting off the highs while it waits on undated 2H-2026 updates.\n- Zipalertinib economics are shared with Taiho and its value event is 2027-02-27, too far out to anchor the current multiple.\n- The name has tripled to a ~$1.05B cap near 52-week highs; a pre-revenue biotech priced this way needs continued good news to hold the level.\n\n## Setup & Price Structure\n- Spot ~$17.10 (2026-07-24), prior close $17.28, market cap ~$1.05B; intraday range that session $17.06–$17.56.\n- 52-week range $5.68 → $19.43; price sits ~12% below the high, consolidating a bull flag that has been drifting lower off the ~$18 area held in early July.\n- The June-data run built a base near $15.77–$16; the flag needs to hold that shelf to keep the rising structure off the $5.68 low intact. A reclaim and weekly close over $19.43 on volume would trigger the breakout.\n- Analyst gap is wide but sell-side-led: median target $30, consensus ~$31.55, range $22–$38 vs ~$17.10 spot — upside exists on paper, but the catalyst that closes it is undated.\n- Fresh entry here is a consolidation buy under a spent-catalyst structure, appropriate only sized for binary clinical risk; there is no hard-dated data event to underwrite oversizing.\n\n## Catalyst Calendar (next 30 days)\n\n- No dated clinical readout falls inside the 30-day window; CLN-978 SLE/RA/Sjögren's updates are guided only to 2H-2026 (undated) — watch for an ACR Convergence (~November 2026) conference slot as the likely next data venue.\n- zipalertinib PDUFA 2027-02-27 (partnered, Taiho) remains the next hard-dated regulatory binary, well outside this window.\n\n## Elapsed catalysts\n\n- 2026-08-07 (est.): Q2-2026 corporate update and financial results — a cash and runway checkpoint, not a data event; treat the surrounding sessions as an earnings-blackout window. *(passed 2d ago)*\n\n## What Would Change Our Mind\n- Bull-confirming: a weekly close above $19.43 on expanding volume alongside a dated 2H-2026 data slot, plus cluster confirmation from CD19/autoimmune peers (Cabaletta, Kyverna) breaking out together — that flips the consolidation back to ACCELERATING and justifies sizing up.\n- Thesis-break condition: a weekly close below $15.77 round-trips the June-data bull flag and the rising structure off the $5.68 low. Confirming evidence would be a CRS or durability miss in expanded CLN-978 cohorts, the CD19-TCE-in-autoimmune theme flipping SATURATED with no replacement leg, or accelerating burn forcing a raise ahead of the 2H data.\n- A negative peer readout (durability or safety failure at Cabaletta/Kyverna or a large-cap bispecific) would pressure the whole theme regardless of CGEM's own tape.\n\n## Correlation Notes\n- Moves with the CD19/BCMA T-cell-engager and CAR-T-in-autoimmune cluster — Cabaletta (CABA), Kyverna (KYTX), and large-cap bispecific programs; a strong or weak peer readout drags the group and can front-run CGEM's own catalysts.\n- Long-duration pre-revenue biotech: carries XBI/small-cap-biotech beta and is rate-sensitive, so a risk-off or tightening macro leg compresses the multiple independent of pipeline news.\n- Zipalertinib ties a slice of the story to the EGFR exon 20 insertion NSCLC space and to partner Taiho's execution, a different correlation vector than the autoimmune lead.",
  "first_seen": "2026-07-10",
  "last_analyzed": "2026-07-26T12:11:05+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}